finance.yahoo.com ·
eli lilly captures 60 glp 205008159
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEli Lilly's strong GLP-1 market share (60%) and rapid uptake of new oral drug Foundayo indicate expanding patient base and pricing power. Revenue and margin expansion for Lilly; competitive pressure on Novo Nordisk and other GLP-1 players. No supply chain or scarcity issues mentioned; impact is company-specific and sector-wide for pharma/biotech.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Eli Lilly Q1 2026 revenue $19.80B, +55.5% YoY
- Net income doubled to $7.40B
- Mounjaro revenue $8.66B, +125%
- Foundayo (orforglipron) 20,000 prescriptions in first 20 days
- Full-year guidance raised to $82-85B
Eli Lilly's Q1 results boost GLP-1 medications sentiment; expect 2-3% upside in 48h.
Sign in to see all sector verdicts, full thesis and counter-argument debate.